Acuta Capital Partners
Acuta Capital Partners reported 23 stocks worth $143M in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are PRAX (19.3%), WHWK (15.0%) and TNGX (8.5%). Compared with Q1 2026, the fund opened new positions in AVBP, FDMT and AVLN, added to WHWK, STRO and SRZN, trimmed PRAX, TNGX and DRUG and sold out of OCS, RVMD and FDMT.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  PRAX Praxis Precision Medicines I | $27.7M | 19.3% | 83K | −2,105 (−2%) | 8 of 8 | |
| 2 |  WHWK Whitehawk Therapeutics Inc | $21.5M | 15.0% | 4.7M | +1.3M (+37%) | 8 of 8 | |
| 3 |  TNGX Tango Therapeutics Inc | $12.2M | 8.5% | 391K | −51K (−12%) | 3 of 8 | |
| 4 |  STRO Sutro Biopharma Inc | $9M | 6.3% | 270K | +826 (+0%) | 3 of 8 | |
| 5 |  AVBP Arrivent Biopharma Inc | $7.6M | 5.3% | 219K | New position | 1 of 8 | |
| 6 |  FDMT 4D Molecular Therapeutics in | $6.8M | 4.7% | 508K | New position | 1 of 8 | |
| 7 |  DRUG Bright Minds Biosciences Inc | $6.5M | 4.5% | 93K | −19K (−17%) | 7 of 8 | |
| 8 |  OCUL Ocular Therapeutix Inc | $5.2M | 3.6% | 532K | −60K (−10%) | 8 of 8 | |
| 9 |  ERAS Erasca Inc | $4.9M | 3.4% | 265K | −89K (−25%) | 2 of 8 | |
| 10 |  SRZN Surrozen Inc | $4.5M | 3.1% | 173K | +548 (+0%) | 6 of 8 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
TERNS PHARMACEUTICALS INC | $26.1M | 496K |
 OCS Oculis Holding AG | $2.6M | 98K |
 RVMD Revolution Medicines Inc | $2.5M | 26K |
FDMT 4D Molecular Therapeutics Inc | $2.3M | 242K |
 IDYA Ideaya Biosciences Inc | $1.6M | 48K |
🔒 Free account: see all 8.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 14, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Acuta Capital Partners 13F FAQ
What does Acuta Capital Partners own?
Acuta Capital Partners reported 23 stocks worth $143M in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are PRAX (19.3%), WHWK (15.0%) and TNGX (8.5%). The table above lists every position in the filing (the top 10 without an account).
What did Acuta Capital Partners buy and sell in Q2 2026?
Compared with Q1 2026: 5 new positions, 9 added to, 6 trimmed and 8 sold out. New positions include AVBP, FDMT and AVLN. It sold all of OCS, RVMD and FDMT.
When will Acuta Capital Partners file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Acuta Capital Partners's portfolio worth?
The Q2 2026 filing reports $143M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.